ALK to spin-off its European veterinary business for undisclosed sum

21 December 2015

Danish allergy specialist ALK-Abello on Monday said it has agreed to sell its European veterinary business to Swedish investment company Fidelio Capital for an undisclosed sum.

The company said it is spinning off the veterinary business including related production facilities in the Netherlands. ALK’s veterinary business specializes in the development, manufacturing and marketing of immunotherapy products for veterinary use. The transaction will be effective as of December 30, 2015, the company said in a statement.

The sale is expected to boost ALK’s full-year outlook on free cash flow by 40-50 million Danish kroner ($5.8-7.3 million). The divestment does not materially impact ALK’s full-year forecast for revenue and earnings before interest, tax, depreciation and amortisation (EBITDA) before special items. The net gain on the sale will be recognised as special items in the profit and loss statement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK